Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects

References

• 1. Zhang Xiaodan, Xiang Qian, Zhao Xia et al. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: a systematic review and meta-analysis. J. Clin. Pharm. Ther. (2018). doi:10.1111/jcpt.12780
  Google Scholar
• 2. Esther Letícia Amorim Ribeiro, de Mendonça Lima Tácio, Bergamini VME et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur. J. Clin. Pharmacol. 74(10), 1215–1233 (2018).
  MedlineGoogle Scholar
• 3. De Berardis D, Rapini G, Olivieri L et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther. Adv. Drug Saf. 9(5), 237–256 (2018).
  MedlineGoogle Scholar
• 4. Aripiprazole therapy and CYP2D6 genotype. In: Medical Genetics Summaries. Dean LPratt VMeleod HRubinstein WMalheiro A (Eds). National Center for Biotechnology Information, MD, USA, 1–9 (2016).
  Google Scholar
• 5. Belmonte C, Ochoa D, Román M et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 39(8), e54–e55 (2017).
  Google Scholar
• 6. Van der Weide K, Van der Weide J. The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J. Clin. Psychopharmacol. 35, 228–236 (2015).
  MedlineGoogle Scholar
• 7. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur. J. Clin. Pharmacol. 72, 175–184 (2016).
  Medline CASGoogle Scholar
• 8. Hendset M, Molden E, Knape M, Hermann M. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther. Drug Monit. 36, 80–85 (2014).
  Medline CASGoogle Scholar
• 9. Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur. J. Clin. Pharmacol. 63, 1147–1151 (2007).
  Medline CASGoogle Scholar
• 10. Andersson T, Flockhart D, Goldstein D et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78, 559–581 (2005).
  Medline CASGoogle Scholar
• 11. Shimizu T, Ochiai H, Asell F et al. Bioinformatics research on interracial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 18, 48–70 (2003).
  Medline CASGoogle Scholar
• 12. Chinese Clinical Trial Registry (ChiCTR). The Chinese clinical trial registry website. www.chictr.org.cn/index.aspx
  Google Scholar
• 13. Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The essentiality of reporting Hardy–Weinberg equilibrium calculations in population-based genetic association studies. Cell J. Summer 17(2), 187–192 (2015).
  MedlineGoogle Scholar
• 14. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 44(2), 179–187 (2013).
  Google Scholar
• 15. Findling RL, Kauffman RE, Sallee FR et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders. J. Clin. Psychopharmacol. 28(4), 441–446 (2008).
  Medline CASGoogle Scholar
• 16. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J. Clin. Pharmacol. 50(6), 659–666 (2010).
  Medline CASGoogle Scholar
• 17. Andersson T, Flockhart D, Goldstein D et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78, 559–581 (2005).
  Medline CASGoogle Scholar
• 18. Shimizu T, Ochiai H, Asell F et al. Bioinformatics research on interracial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes. Drug Metab. Pharmacokinet. 18, 71–78 (2003).
  Medline CASGoogle Scholar
• 19. Furman K, Grimm D, Mueller T et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 14, 279–284 (2004).
  Medline CASGoogle Scholar